Your browser doesn't support javascript.
loading
Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia.
Gotti, Giacomo; Stevenson, Kristen; Kay-Green, Samantha; Blonquist, Traci M; Mantagos, Jason S; Silverman, Lewis B; Place, Andrew E.
Afiliação
  • Gotti G; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Stevenson K; Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Kay-Green S; Pediatric Hematology-Oncology, University of Milano-Bicocca, MBBM Foundation, Monza, Italy.
  • Blonquist TM; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Massachusetts, USA.
  • Mantagos JS; Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Silverman LB; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Massachusetts, USA.
  • Place AE; Department of Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, USA.
Pediatr Blood Cancer ; 69(4): e29542, 2022 04.
Article em En | MEDLINE | ID: mdl-35187841
ABSTRACT

BACKGROUND:

Ocular abnormalities (OA) in pediatric patients with acute lymphoblastic leukemia (ALL) are common findings both at diagnosis and later in follow-up. The frequency, predictors, and prognostic impact of OA in the context of recent ALL protocols are not well characterized. PROCEDURE Single-center retrospective analysis of the medical records of 224 patients with ALL enrolled on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 05-001.

RESULTS:

Overall, 217 (98%) patients had at least one ophthalmic exam. Retinal hemorrhages were the most frequent abnormalities at diagnosis (11%) and cataracts at later time points (13%). OA at diagnosis were associated with age ≥10 years and with the severity of anemia and thrombocytopenia; they were also univariately associated with lower 5-year event-free survival (EFS) (high risk [HR] = 3.09 [95% CI 1.38-6.94]; p = .006), but not in a disease-free survival (DFS) model adjusted for end-induction minimal residual disease (p = .82). The cumulative incidence of cataract was 13.1% ± 2.8% at 43 months from diagnosis; its development was associated with high presenting white blood cell count (≥50,000/µl) (p = .010), male sex (p = .036), higher risk group (p = .025), and cranial radiation (p = .004). Cataract was associated with decreased visual acuity.

CONCLUSIONS:

OA at diagnosis, present in 12% of patients, were associated with older age, anemia, and thrombocytopenia and did not carry a significant prognostic impact. Cataracts were detected in over 10% of patients and were associated with decreased visual acuity, thus supporting routine screening after completion of therapy, especially for those treated with high-risk protocols.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombocitopenia / Catarata / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Humans / Infant / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombocitopenia / Catarata / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Humans / Infant / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article